Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-19
2009-12-08
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026230, C536S026260, C536S026700, C536S027200
Reexamination Certificate
active
07629320
ABSTRACT:
Disclosed are β-D-ribofuranosyl-pyrazolo[3,4-d]pyrimidine compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Representative compounds include those having the general formula.
REFERENCES:
patent: 5430027 (1995-07-01), Knutsen et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763167 (1998-06-01), Conrad
patent: 5977332 (1999-11-01), Martin
patent: 6211154 (2001-04-01), Scarborough et al.
patent: 6475985 (2002-11-01), Wagner et al.
patent: 6500946 (2002-12-01), Takamatsu et al.
patent: 6586413 (2003-07-01), Liang et al.
patent: 6660721 (2003-12-01), Devos et al.
patent: 6703394 (2004-03-01), Engelhardt et al.
patent: 7425547 (2008-09-01), Roberts et al.
patent: 2003/0130226 (2003-07-01), Loakes et al.
patent: 2007/0015905 (2007-01-01), LaColla et al.
patent: 2007/0032449 (2007-02-01), LaColla et al.
patent: 1117669 (2001-07-01), None
patent: WO 94/18215 (1994-08-01), None
patent: WO 95/07919 (1995-03-01), None
patent: WO 2002/057425 (2002-07-01), None
patent: WO2003/061576 (2003-07-01), None
patent: WO 2004/002848 (2004-01-01), None
patent: WO 2004/065398 (2004-08-01), None
[R] Bowler et al., “New Adenosine A3 Ligands Controlling Cytokines,” Drug Development Research, 37, 173 (bottom of col. 2) (Mar. 1996); disclosed in the parent case.
(S) Jacobson et al., “Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors,” Drug Development Research, 39(3-4), 289-300 (1996); disclosed in the parent case.
Beigelman et al. “New Syntheses of 2'-C-Methylnucleosides Starting from D-Glucose and D-Ribose”Carbo. Research, 166:219-232 (1987).
Bowler et al., “New Adenosine A3 Ligands Controlling Cytokines,”Drug Development Research, 37, 173 (bottom of col. 2) (Mar. 1996).
Jacobson et al., “Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors,”Drug Development Research, 39(3-4), 289-300 (1996).
Dyatkina Natalia B.
Roberts Christopher D.
Crane Lawrence E
SmithKline Beecham Corporation
Thomas Robert (Steve)
LandOfFree
Nucleoside derivatives for treating hepatitis C virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside derivatives for treating hepatitis C virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives for treating hepatitis C virus infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133231